According to a new report published by K D Market Insights, titled, “Epigenetics Market Insights, Trends, Opportunity & Forecast, 2023–2032,” the global epigenetics market size is anticipated to witness moderate growth during the forecast period i.e., 2023-2032. The considerable advancements in research and development in epigenetics, Chronic ailments such as cancer, cardiovascular diseases, metabolic illnesses, and neurological diseases are on the upward push globally, Personalized medication demand on the rise, technological advancements in epigenetics and increasing funding for epigenetics research. Which are the major factors augmenting the growth of the global epigenetics market. The global epigenetics market is anticipated to grow at a high CAGR of 16.1% from 2023 to 2032. The market's revenue surged to $1.7 billion in 2022, and it is expected to further accelerate, reaching a notable $7.5 billion by 2032.

The discipline of epigenetics has seen considerable advancements in research and development, leading to a deeper understanding of epigenetic mechanisms and their function in various diseases, are further expected to create ample growth opportunities for the global epigenetics market during the forecast period i.e., 2023-2032. Moreover, chronic ailments such as cancer, cardiovascular diseases, metabolic illnesses, and neurological diseases are on the upward push globally, has propelled market expansion. Governments, research institutions, and private agencies are increasingly making an investment in epigenetics studies, is expected to contribute towards the market growth during the period.

The North America region accounted for the largest share in the global epigenetics market in 2022. The region is further projected to continue dominating in the market during the forecast period. This can be attributed to the emphasis on cancer research, drug discovery in academic and research institutes

According to application, the oncology segment accounted for the largest market share in the epigenetics market in 2022 and is further expected to continue with the trend during the forecast period i.e., 2023 – 2032.

The global epigenetics market is segmented into product, application, end-users and region. Based on product, the market is bifurcated into kits, reagents, enzymes, instruments. Based on application, it is classified into oncology, metabolic diseases, immunology, developmental biology, cardiovascular diseases, other applications. Based on end-users, it is classified into academic and research institutes, pharmaceutical and biotechnology companies, contract research organizations.

The global epigenetics market is analyzed across North America (U.S. & Canada), Europe (Germany, United Kingdom, France, Italy, Spain, Russia, and Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Indonesia, Thailand, Australia, New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and the Rest of Latin America) and Middle East & Africa (GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, and Rest of Middle East & Africa).

Key Insights of Epigenetics Market

  • On the basis of application, the oncology segment accounted for the largest market share in the epigenetics market in 2022 and is further expected to continue with the trend during the forecast period i.e., 2023 – 2032.
  • On the basis of region, North America accounted for the largest share in the global epigenetics market in 2022. The region is further projected to continue dominating in the market during the forecast period.
  • On the basis of region, Asia-Pacific is estimated to account for the second largest share in the market during the forecast period.

Some of the major epigenetics companies profiled in the report include Thermo Fisher Scientific, Merck KGaA, Illumina, Inc., PacBio, Abcam plc, Active Motif, Inc., Bio-Rad Laboratories, Promega Corporation, PerkinElmer, Qiagen, New England Biolabs, Zymo Research Corporation, Diagenode, F. Hoffmann-La Roche Ltd.

Related Reports :-

https://www.kdmarketinsights.com/reports/autoimmune-disease-drug-market/7134

https://www.kdmarketinsights.com/reports/antifungal-drugs-market/7133

https://www.kdmarketinsights.com/reports/alopecia-treatment-market-1/7131

https://www.kdmarketinsights.com/reports/traumatic-brain-injury-treatment-market/7127